- Trials with a EudraCT protocol (236)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (15)
236 result(s) found for: Enteritis.
Displaying page 1 of 12.
EudraCT Number: 2005-003943-30 | Sponsor Protocol Number: VomED | Start Date*: 2005-11-22 | |||||||||||
Sponsor Name:University of Leipzig | |||||||||||||
Full Title: Doubleblind randomized multicenter trial to investigate the influence of dimenhydrinate suppositories vs. placebo on oral rehydration in infants and children with infectious enteritis and vomiting | |||||||||||||
Medical condition: Infectious enteritis with vomiting | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-010163-16 | Sponsor Protocol Number: 08/0285 | Start Date*: 2009-06-05 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: Bile salt manipulation as a novel treatment for Crohn’s disease: a single centre open label pilot study of atorvastatin and colesevalam in patients with active ileal Crohn’s disease | ||||||||||||||||||
Medical condition: Active Crohn's disease affecting the ileum | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-011763-37 | Sponsor Protocol Number: ADAVEGF-01 | Start Date*: 2009-07-22 | |||||||||||
Sponsor Name:ISTITUTO CLINICO HUMANITAS | |||||||||||||
Full Title: THE ANTI-ANGIOGENIC EFFECTS OF ADALIMUMAB IN CROHN`S DISEASE | |||||||||||||
Medical condition: Crohn`s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-001324-31 | Sponsor Protocol Number: 16/2008/O/Sper | Start Date*: 2008-07-09 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Efficacy and security of oral supplementation with a probiotic (Lactobacillus reuteri) in newborns with birth weight < 1500 g: effects on necrotising enterocolitis (NEC) and gut colonization with g... | |||||||||||||
Medical condition: necrotising enterocolitis (NEC | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001278-13 | Sponsor Protocol Number: PROSIBD | Start Date*: 2016-06-08 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Taina Sipponen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Immunologic, genetic and microbiomic predictors of the treatment response for TNFalpha-blocking drugs – prospective follow-up cohort of patients with Crohn’s disease or ulcerative colitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Ulcerative colitis and Crohn's disease | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013348-35 | Sponsor Protocol Number: 7915 | Start Date*: 2009-08-04 | |||||||||||||||||||||
Sponsor Name:University Medical Center Utrecht | |||||||||||||||||||||||
Full Title: (Patho)Physiological aspects of the bile salt-FXR-FGF19-axis: potential consequences in Crohn's disease. | |||||||||||||||||||||||
Medical condition: Patients with quiescent Crohn’s colitis, defined as a Crohn’s Disease Activity Index <150 ; non-IBD patients will serve as disease controls. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003508-12 | Sponsor Protocol Number: 010-01 | Start Date*: 2006-02-28 | |||||||||||
Sponsor Name:Merck and Co., Inc. | |||||||||||||
Full Title: Safety and Immunogenicity of Concomitant Use of RotaTeq™ and INFANRIX™ Hexa in Healthy Children | |||||||||||||
Medical condition: RotaTeq is an oral pentavalent vaccine indicated for the prevention of rotavirus gastroenteritis in infants and children caused by the serotypes G1, G2, G3, G4, and G-serotypes that contain P1 (e.g... | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000263-32 | Sponsor Protocol Number: V260-028 | Start Date*: 2017-03-07 | |||||||||||
Sponsor Name:Merck & Co., Inc. | |||||||||||||
Full Title: A Double-Blind, Randomized, Placebo-Controlled, Safety and Tolerability Study of Live Pentavalent Human-Bovine Rotavirus Reassortant Vaccine in Chinese Healthy Adults, Children and Infants | |||||||||||||
Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000264-15 | Sponsor Protocol Number: V260-029 | Start Date*: 2017-03-07 | |||||||||||
Sponsor Name:Banyu Pharmaceutical Co., Ltd. a subsidiary of Merck & Co.,Inc, Kenilworth, New Jersey, USA | |||||||||||||
Full Title: A phase III randomized, placebo-controlled clinical trial to study the efficacy and safety of V260 in healthy infants in Japan | |||||||||||||
Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000786-24 | Sponsor Protocol Number: NET-2013-02355002 | Start Date*: 2017-03-07 | |||||||||||
Sponsor Name:IRCCS Burlo Garofolo | |||||||||||||
Full Title: Thalidomide, a novel immunological treatment to modify the natural history of paediatric Crohn's disease: a new proposal from a well-established paediatric research network | |||||||||||||
Medical condition: Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005966-39 | Sponsor Protocol Number: TJT1123 | Start Date*: 2012-03-08 | ||||||||||||||||||||||||||
Sponsor Name:CHU-ULg | ||||||||||||||||||||||||||||
Full Title: Mesenchymal stem cell therapy for the treatment of severe or refractory inflammatory and/or autoimmune disorders. | ||||||||||||||||||||||||||||
Medical condition: Crohn's disease | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: BE (Completed) | ||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002494-48 | Sponsor Protocol Number: version 1.0, 02 May 2006 | Start Date*: 2006-09-27 | |||||||||||
Sponsor Name:University College London / University College London Hospitals NHS Foundation Trust | |||||||||||||
Full Title: Sildenafil in Crohn’s disease: an open label pilot study of Sildenafil in 15 patients with active colonic Crohn’s disease | |||||||||||||
Medical condition: Active colonic Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-001754-28 | Sponsor Protocol Number: A3921084 | Start Date*: 2012-06-05 | |||||||||||
Sponsor Name:Pfizer Inc.235 East 42nd Street, New York, NY 10017, USA | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTRE STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF CP-690,550 FOR MAINTENANCE THERAPY IN SUBJECTS WITH MODERATE TO SEVERE C... | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) SE (Prematurely Ended) HU (Completed) ES (Completed) AT (Completed) NL (Completed) CZ (Completed) GR (Completed) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-001866-14 | Sponsor Protocol Number: 3150-303-008 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: An Open-label, Long-term Extension Study of Brazikumab in Participants with Moderately to Severely Active Crohn’s Disease | |||||||||||||
Medical condition: Moderately to Severely Active Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) ES (Prematurely Ended) DE (Completed) CZ (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002981-19 | Sponsor Protocol Number: IM129-008 | Start Date*: 2012-02-14 | ||||||||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | ||||||||||||||||||
Full Title: A Phase IIa, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Clinical Efficacy and Safety of Induction and Maintenance Therapy with BMS-936557 in Subjects with Active Crohn's Dis... | ||||||||||||||||||
Medical condition: CROHN’S DISEASE | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: BE (Completed) HU (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000598-19 | Sponsor Protocol Number: 115461 | Start Date*: 2016-10-28 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks. | |||||||||||||
Medical condition: Rotarix is indicated to prevent infants against gastroenteritis (GE) due to rotavirus (RV). | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) DE (Completed) Outside EU/EEA ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000277-37 | Sponsor Protocol Number: V260-060 | Start Date*: 2017-03-10 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: Post-marketing, Randomized, Open-label Study to Assess the Immunogenicity and Safety of Concomitant Administration of V260 and Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP... | |||||||||||||
Medical condition: Prevention of Rotavirus Gastroenteritis Caused by Serotypes G1, G2, G3, G4, and G-Serotypes Associated With P1A [8] (e.g., G9) in Infants | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000529-31 | Sponsor Protocol Number: 20110232 | Start Date*: 2012-11-09 | |||||||||||
Sponsor Name:Amgen Inc | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 181 in Subjects with Moderate to Severe Crohn’s Disease | |||||||||||||
Medical condition: Moderate to severe Crohn's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) CZ (Completed) DK (Prematurely Ended) DE (Prematurely Ended) AT (Completed) HU (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006484-36 | Sponsor Protocol Number: FARM79YXLN | Start Date*: 2009-04-16 | |||||||||||
Sponsor Name:AZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA | |||||||||||||
Full Title: MULTICENTER COMPARATIVE STUDY BETWEEN NUTRITIONAL THERAPY ALONE AND ANTI-TNF-alpha MONOCLONAL ANTIBODY IN INDUCING AND MAINTAINING REMISSION IN PEDIATRIC CROHN`S DISEASE: A RANDOMIZED CONTROLLED TRIAL | |||||||||||||
Medical condition: Moderate-to-severe active Crohn`s disease. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010727-91 | Sponsor Protocol Number: 00695 | Start Date*: 2011-03-01 | |||||||||||
Sponsor Name:LMU München, Campus Großhadern | |||||||||||||
Full Title: Colesevelam for the treatment of bile acid malabsorption in patients with Crohn’s disease (Colesevelam für die Therapie der Gallensäuren-Malabsorption bei M. Crohn-Patienten) | |||||||||||||
Medical condition: Morbus Crohn | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
